Loading…
Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer
Background Recent studies have demonstrated that acetyl‐CoA synthetase 2 (ACSS2) plays a critical role in cancer cell survival; however, the role of ACSS2 in gastric carcinogenesis has not been determined. Methods We investigated the expression of ACSS2 in human gastric cancer (GC) tissues using imm...
Saved in:
| Published in: | Journal of surgical oncology 2015-11, Vol.112 (6), p.585-591 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4613-7d6e94a3b06ecbd1a1b9e05de0f7a22fb5e7cd24e6f9745b9e4ce7265e88a29a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4613-7d6e94a3b06ecbd1a1b9e05de0f7a22fb5e7cd24e6f9745b9e4ce7265e88a29a3 |
| container_end_page | 591 |
| container_issue | 6 |
| container_start_page | 585 |
| container_title | Journal of surgical oncology |
| container_volume | 112 |
| creator | Hur, Hoon Kim, Young-Bae Ham, In-Hye Lee, Dakeun |
| description | Background
Recent studies have demonstrated that acetyl‐CoA synthetase 2 (ACSS2) plays a critical role in cancer cell survival; however, the role of ACSS2 in gastric carcinogenesis has not been determined.
Methods
We investigated the expression of ACSS2 in human gastric cancer (GC) tissues using immunohistochemistry, and analyzed its clinicopathological correlation and prognostic relevance.
Results
Among 350 GCs, 219 cases (62.6%) were classified as ACSS2‐low, whereas 131 cases (37.4%) were ACSS2‐high. Loss of ACSS2 expression (ACSS2‐low) was more frequently observed in undifferentiated histology (P = 0.002), in cases with MLH1‐loss (P = 0.003), and in cases with SIRT3‐low (P |
| doi_str_mv | 10.1002/jso.24043 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1726791682</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3846875971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4613-7d6e94a3b06ecbd1a1b9e05de0f7a22fb5e7cd24e6f9745b9e4ce7265e88a29a3</originalsourceid><addsrcrecordid>eNp1kEtPAyEUhYnR2PpY-AfMJK5cjALDwLCs9Z3GR6p2SRjmTqXqUGGa1n8vOurOFZDznXMvB6E9go8IxvR4FtwRZZhla6hPsOSpxLJYR_2o0ZQJiXtoK4QZxlhKzjZRj_KsIJjRProbuRASVyeD4XhME1jNPYRgXZPES2VNG5K5cz6-3LRxwYbERkm3FpooLW37nEx1aL01idGNAb-DNmr9GmD359xGj-dnD8PLdHR7cTUcjFLDOMlSUXGQTGcl5mDKimhSSsB5BbgWmtK6zEGYijLgtRQsjyIzICjPoSg0lTrbRgddbtzsfQGhVTO38E0cqUjkhCS8oJE67Cjj4z891Gru7Zv2H4pg9dWdit2p7-4iu_-TuCjfoPojf8uKwHEHLO0rfPyfpK7Ht7-RaeewoYXVn0P7F8VFJnI1ublQd6cT_lSc3Kun7BNplYgD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1726791682</pqid></control><display><type>article</type><title>Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Hur, Hoon ; Kim, Young-Bae ; Ham, In-Hye ; Lee, Dakeun</creator><creatorcontrib>Hur, Hoon ; Kim, Young-Bae ; Ham, In-Hye ; Lee, Dakeun</creatorcontrib><description>Background
Recent studies have demonstrated that acetyl‐CoA synthetase 2 (ACSS2) plays a critical role in cancer cell survival; however, the role of ACSS2 in gastric carcinogenesis has not been determined.
Methods
We investigated the expression of ACSS2 in human gastric cancer (GC) tissues using immunohistochemistry, and analyzed its clinicopathological correlation and prognostic relevance.
Results
Among 350 GCs, 219 cases (62.6%) were classified as ACSS2‐low, whereas 131 cases (37.4%) were ACSS2‐high. Loss of ACSS2 expression (ACSS2‐low) was more frequently observed in undifferentiated histology (P = 0.002), in cases with MLH1‐loss (P = 0.003), and in cases with SIRT3‐low (P < 0.001). The ACSS2‐low cases showed significantly lower mean disease‐free survival (DFS, 68.5 vs. 81.8 months; P = 0.025) and overall survival (OS, 73.5 vs. 86.6 months; P = 0.029). In multivariate analysis, loss of ACSS2 expression was identified as one of the independent prognostic factors predicting worse DFS (HR: 1.547, P = 0.018) and OS (HR: 1.476, P = 0.036).
Conclusions
We revealed that the loss of ACSS2 expression is a reliable independent poor prognostic factor in GC. Our results may expand our understanding of the involvement of glucose metabolism, including the role of ACSS2, in the pathogenesis of GC. J. Surg. Oncol. 2015;112:585–591. © 2015 Wiley Periodicals, Inc.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.24043</identifier><identifier>PMID: 26381042</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Acetate-CoA Ligase - metabolism ; ACSS2 ; Adenocarcinoma - metabolism ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma, Mucinous - metabolism ; Adenocarcinoma, Mucinous - mortality ; Adenocarcinoma, Mucinous - pathology ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - metabolism ; Carcinoma, Signet Ring Cell - metabolism ; Carcinoma, Signet Ring Cell - mortality ; Carcinoma, Signet Ring Cell - pathology ; Female ; Follow-Up Studies ; gastric cancer ; Humans ; Immunoenzyme Techniques ; Male ; microsatellite instability ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Staging ; Prognosis ; SIRT3 ; Stomach Neoplasms - metabolism ; Stomach Neoplasms - mortality ; Stomach Neoplasms - pathology ; Survival Rate ; Tissue Array Analysis ; Young Adult</subject><ispartof>Journal of surgical oncology, 2015-11, Vol.112 (6), p.585-591</ispartof><rights>2015 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4613-7d6e94a3b06ecbd1a1b9e05de0f7a22fb5e7cd24e6f9745b9e4ce7265e88a29a3</citedby><cites>FETCH-LOGICAL-c4613-7d6e94a3b06ecbd1a1b9e05de0f7a22fb5e7cd24e6f9745b9e4ce7265e88a29a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26381042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hur, Hoon</creatorcontrib><creatorcontrib>Kim, Young-Bae</creatorcontrib><creatorcontrib>Ham, In-Hye</creatorcontrib><creatorcontrib>Lee, Dakeun</creatorcontrib><title>Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer</title><title>Journal of surgical oncology</title><addtitle>J. Surg. Oncol</addtitle><description>Background
Recent studies have demonstrated that acetyl‐CoA synthetase 2 (ACSS2) plays a critical role in cancer cell survival; however, the role of ACSS2 in gastric carcinogenesis has not been determined.
Methods
We investigated the expression of ACSS2 in human gastric cancer (GC) tissues using immunohistochemistry, and analyzed its clinicopathological correlation and prognostic relevance.
Results
Among 350 GCs, 219 cases (62.6%) were classified as ACSS2‐low, whereas 131 cases (37.4%) were ACSS2‐high. Loss of ACSS2 expression (ACSS2‐low) was more frequently observed in undifferentiated histology (P = 0.002), in cases with MLH1‐loss (P = 0.003), and in cases with SIRT3‐low (P < 0.001). The ACSS2‐low cases showed significantly lower mean disease‐free survival (DFS, 68.5 vs. 81.8 months; P = 0.025) and overall survival (OS, 73.5 vs. 86.6 months; P = 0.029). In multivariate analysis, loss of ACSS2 expression was identified as one of the independent prognostic factors predicting worse DFS (HR: 1.547, P = 0.018) and OS (HR: 1.476, P = 0.036).
Conclusions
We revealed that the loss of ACSS2 expression is a reliable independent poor prognostic factor in GC. Our results may expand our understanding of the involvement of glucose metabolism, including the role of ACSS2, in the pathogenesis of GC. J. Surg. Oncol. 2015;112:585–591. © 2015 Wiley Periodicals, Inc.</description><subject>Acetate-CoA Ligase - metabolism</subject><subject>ACSS2</subject><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma, Mucinous - metabolism</subject><subject>Adenocarcinoma, Mucinous - mortality</subject><subject>Adenocarcinoma, Mucinous - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Carcinoma, Signet Ring Cell - metabolism</subject><subject>Carcinoma, Signet Ring Cell - mortality</subject><subject>Carcinoma, Signet Ring Cell - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>gastric cancer</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Male</subject><subject>microsatellite instability</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>SIRT3</subject><subject>Stomach Neoplasms - metabolism</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - pathology</subject><subject>Survival Rate</subject><subject>Tissue Array Analysis</subject><subject>Young Adult</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kEtPAyEUhYnR2PpY-AfMJK5cjALDwLCs9Z3GR6p2SRjmTqXqUGGa1n8vOurOFZDznXMvB6E9go8IxvR4FtwRZZhla6hPsOSpxLJYR_2o0ZQJiXtoK4QZxlhKzjZRj_KsIJjRProbuRASVyeD4XhME1jNPYRgXZPES2VNG5K5cz6-3LRxwYbERkm3FpooLW37nEx1aL01idGNAb-DNmr9GmD359xGj-dnD8PLdHR7cTUcjFLDOMlSUXGQTGcl5mDKimhSSsB5BbgWmtK6zEGYijLgtRQsjyIzICjPoSg0lTrbRgddbtzsfQGhVTO38E0cqUjkhCS8oJE67Cjj4z891Gru7Zv2H4pg9dWdit2p7-4iu_-TuCjfoPojf8uKwHEHLO0rfPyfpK7Ht7-RaeewoYXVn0P7F8VFJnI1ublQd6cT_lSc3Kun7BNplYgD</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Hur, Hoon</creator><creator>Kim, Young-Bae</creator><creator>Ham, In-Hye</creator><creator>Lee, Dakeun</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>20151101</creationdate><title>Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer</title><author>Hur, Hoon ; Kim, Young-Bae ; Ham, In-Hye ; Lee, Dakeun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4613-7d6e94a3b06ecbd1a1b9e05de0f7a22fb5e7cd24e6f9745b9e4ce7265e88a29a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acetate-CoA Ligase - metabolism</topic><topic>ACSS2</topic><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma, Mucinous - metabolism</topic><topic>Adenocarcinoma, Mucinous - mortality</topic><topic>Adenocarcinoma, Mucinous - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Carcinoma, Signet Ring Cell - metabolism</topic><topic>Carcinoma, Signet Ring Cell - mortality</topic><topic>Carcinoma, Signet Ring Cell - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>gastric cancer</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Male</topic><topic>microsatellite instability</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>SIRT3</topic><topic>Stomach Neoplasms - metabolism</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - pathology</topic><topic>Survival Rate</topic><topic>Tissue Array Analysis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hur, Hoon</creatorcontrib><creatorcontrib>Kim, Young-Bae</creatorcontrib><creatorcontrib>Ham, In-Hye</creatorcontrib><creatorcontrib>Lee, Dakeun</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hur, Hoon</au><au>Kim, Young-Bae</au><au>Ham, In-Hye</au><au>Lee, Dakeun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J. Surg. Oncol</addtitle><date>2015-11-01</date><risdate>2015</risdate><volume>112</volume><issue>6</issue><spage>585</spage><epage>591</epage><pages>585-591</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background
Recent studies have demonstrated that acetyl‐CoA synthetase 2 (ACSS2) plays a critical role in cancer cell survival; however, the role of ACSS2 in gastric carcinogenesis has not been determined.
Methods
We investigated the expression of ACSS2 in human gastric cancer (GC) tissues using immunohistochemistry, and analyzed its clinicopathological correlation and prognostic relevance.
Results
Among 350 GCs, 219 cases (62.6%) were classified as ACSS2‐low, whereas 131 cases (37.4%) were ACSS2‐high. Loss of ACSS2 expression (ACSS2‐low) was more frequently observed in undifferentiated histology (P = 0.002), in cases with MLH1‐loss (P = 0.003), and in cases with SIRT3‐low (P < 0.001). The ACSS2‐low cases showed significantly lower mean disease‐free survival (DFS, 68.5 vs. 81.8 months; P = 0.025) and overall survival (OS, 73.5 vs. 86.6 months; P = 0.029). In multivariate analysis, loss of ACSS2 expression was identified as one of the independent prognostic factors predicting worse DFS (HR: 1.547, P = 0.018) and OS (HR: 1.476, P = 0.036).
Conclusions
We revealed that the loss of ACSS2 expression is a reliable independent poor prognostic factor in GC. Our results may expand our understanding of the involvement of glucose metabolism, including the role of ACSS2, in the pathogenesis of GC. J. Surg. Oncol. 2015;112:585–591. © 2015 Wiley Periodicals, Inc.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>26381042</pmid><doi>10.1002/jso.24043</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2015-11, Vol.112 (6), p.585-591 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_proquest_journals_1726791682 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Acetate-CoA Ligase - metabolism ACSS2 Adenocarcinoma - metabolism Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma, Mucinous - metabolism Adenocarcinoma, Mucinous - mortality Adenocarcinoma, Mucinous - pathology Adult Aged Aged, 80 and over Biomarkers, Tumor - metabolism Carcinoma, Signet Ring Cell - metabolism Carcinoma, Signet Ring Cell - mortality Carcinoma, Signet Ring Cell - pathology Female Follow-Up Studies gastric cancer Humans Immunoenzyme Techniques Male microsatellite instability Middle Aged Neoplasm Invasiveness Neoplasm Staging Prognosis SIRT3 Stomach Neoplasms - metabolism Stomach Neoplasms - mortality Stomach Neoplasms - pathology Survival Rate Tissue Array Analysis Young Adult |
| title | Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T04%3A04%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Loss%20of%20ACSS2%20expression%20predicts%20poor%20prognosis%20in%20patients%20with%20gastric%20cancer&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Hur,%20Hoon&rft.date=2015-11-01&rft.volume=112&rft.issue=6&rft.spage=585&rft.epage=591&rft.pages=585-591&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.24043&rft_dat=%3Cproquest_cross%3E3846875971%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4613-7d6e94a3b06ecbd1a1b9e05de0f7a22fb5e7cd24e6f9745b9e4ce7265e88a29a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1726791682&rft_id=info:pmid/26381042&rfr_iscdi=true |